Macular Degeneration UPDATE Winter 2022


A newsletter devoted to the most current medical, social and psychological aspects of all visual diseases



By Dr. Joshua Mali

I am very excited to announce my top 5 new eye treatments that were recently

approved by the FDA:

1) Susvimo

The recent FDA approval of Genentech’s Susvimo, previously called the Port Delivery System (PDS) with ranibizumab (Lucentis, Genentech), the first wet, or neovascular, AMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a month. The drug is billed as a first-of-its-kind therapeutic approach for wet age-related macular degeneration (AMD) and may help people with the disease maintain their vision with as few as 2 treatments annually. The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every 6 months. According to Genentech, Susvimo will be available in the United States in the coming months and the company is committed to helping patients access the medicines they are prescribed and will be offering comprehensive services for people prescribed Susvimo to help minimize barriers to access and reimbursement. Susvimo represents a big victory for patients with wet AMD and it is an honor for me as a retinal specialist to provide my patients with the most cutting-edge technology to give them the best vision possible.

2) Vuity

Recently announced, the FDA has approved of pilocarpine HCl ophthalmic solution 1.25% (VUITY) for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. According to the company, pilocarpine HCl ophthalmic solution 1.25% is the first and only FDA-approved eye drop to treat this common and progressive eye condition that affects 128 million Americans, nearly half of the US adult population. Pilocarpine HCl ophthalmic solution 1.25% is a daily, prescription eye drop that works in as early as 15 minutes and lasts up to 6 hours, as measured on day 30, to improve near and intermediate vision without

impacting distance vision. Specifically designed for presbyopia, pilocarpine HCl ophthalmic solution 1.25% is an optimized formulation of pilocarpine, an established eye care therapeutic, delivered with pHast technology. The proprietary pHast technology allows pilocarpine HCl ophthalmic solution 1.25% to rapidly adjust to the physiologic pH of the tear film. Pilocarpine HCl ophthalmic solution 1.25% uses the eye’s own ability to reduce pupil size, improving near vision without affecting distance vision. VUITY represents a big victory for patients with presbyopia and it is an honor for me as a board certified ophthalmologist to provide my patients with the most cutting-edge treatments to give them the best vision possible.

3) Tyrvaya

Probably one of the more interesting treatments, Tyrvaya is the first and only nasal spray approved by the FDA for the treatment of dry eye disease. The Nasal Spray is believed

to bind to cholinergic receptors to activate the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease. Tyrvava Nasal Spray is a highly selective cholinergic agonist delivered twice daily as an aqueous nasal spray into each nostril to activate basal tear production. Nasal spray administration provides a new way to treat dry eye disease without administering medication onto an already irritated ocular surface. In addition, nasal delivery may allow some patients who have difficulty independently administering topical eye drops to administer independently their prescribed dry eye disease therapy. Certainly, an interesting treatment to keep an eye on!


Chairman’s Column | Winter Edition 2021


Greetings friends,

As an organization, our promise is to serve the macular degeneration community through patient outreach and educational programs. We have also added diabetic eye disease as requested by our supporters. Throughout this past year, we have been fortunate in partnering with wonderful sponsors and other community organizations allowing us to fulfill our mission. These awareness and educational initiatives allow the association to provide information about research, risk factors, genetic predisposition, and proper diagnosis, as well as preventive efforts, advances within the agerelated macular degeneration and diabetic eye disease fields, and various treatment options. This past year, our journey in meeting and hosting educational programs around the country brought a new meaning to our mission and touched our lives in ways we have never imagined. Everyone has a different story, experience, and understanding of what macular degeneration is and how it can affect your life along with diabetic eye disease. This inspired everyone at the association to willfully create a robust strategic plan for 2022. We have been collaborating with our partners to host fourteen educational in person programs and six virtual programs around the country throughout 2022. With the new COVID variants, travel may become restricted, and the programs would then revert to virtual seminars. There will also be additional programs added. Check the MDA website for up-to-date information of these programs. www.MacularHope.org. We will work tirelessly to distribute valuable information about macular degeneration and the advances through various clinical trials and research.

We have been fortunate to see firsthand how the advances within age-related macular degeneration have transpired and look forward to new therapies and treatment options in hopes of finding a cure to this sight-stealing disease. The Macular Degeneration Association would like to invite you to participate in whatever capacity you may be able to throughout the upcoming year and hope that you will continue to join us along our journey. Cheers to an exciting year ahead. Happy New Year Friends!



Lawrence Hoffheimer

MDA Chairman of the Board



Coming Soon Matter of Vision!


We are working on schedules for 14 live in cities below

programs & 6 Virtual programs currently. Once we have the

confirmation of dates and times it will be on our website:


Live programs will be conducted in the following cities:

Phoenix, AZ, Madison, WI,

Asheville, NC, Tucson, AZ,

Fort Lauderdale, FL Skokie, IL,

Seattle, WA, Colorado Springs, CO,

Columbus, OH, North Charleston, SC

Portland, OR, San Antonia, TX,

Atlanta, GA Ocala, FL

If you would like an email when the program dates are

scheduled, please send us your email address and we will

send you the information once it is available.


New Eye Drop for Presbyopia: You bet! | By Dr. Joshua Mali


Allergan, an AbbVie company, announced FDA approval of pilocarpine HCl ophthalmic solution 1.25% (VUITY) for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. According to the company, pilocarpine HCl ophthalmic solution 1.25% is the first and only FDA-approved eye drop to treat this common and progressive eye condition that affects 128 million Americans, nearly half of the US adult population. Pilocarpine HCl ophthalmic solution 1.25% is a daily, prescription eye drop that works in as early as 15 minutes and lasts up to 6 hours, as measured on day 30, to improve near and intermediate vision without impacting distance vision. Specifically designed for presbyopia, pilocarpine HCl ophthalmic solution 1.25% is an optimized formulation of pilocarpine, an established eye care therapeutic, delivered with pHast technology. The proprietary pHast technology allows pilocarpine HCl ophthalmic solution 1.25% to rapidly adjust to the physiologic pH of the tear film. Pilocarpine HCl ophthalmic solution 1.25% uses the eye’s own ability to reduce pupil size, improving near vision without affecting distance vision.

The FDA approval of VUITY is based on data from two pivotal phase 3 clinical studies, GEMINI 1 and GEMINI 2, which evaluated the efficacy, safety and tolerability of VUITY for the treatment of presbyopia. In both studies, the drops met the primary endpoint, reaching statistical significance in improvement in near vision in low light (mesopic) conditions without a loss of distance vision versus the vehicle (placebo) on day 30 at hour 3. Additionally, improvement was seen as early as 15 minutes and lasted through 6 hours. There were no serious adverse events observed in participants receiving VUITY in either the GEMINI 1 or GEMINI 2 study. VUITY represents a big victory for patients with presbyopia and it is an honor for me as a board-certified ophthalmologist to provide my patients with the most cutting-edge treatments to give them the best vision possible. Joshua Mali, MD, is a board-certified ophthalmologist and award-winning vitreoretinal surgeon at The Eye Associates, a private multi-specialty ophthalmology practice in Sarasota, Florida. He is the Retina Medical Director of the Macular Degeneration Association (MDA). He is also the Founder & CEO of Mali Enterprises




By: Joshua Mali, M.D.


It started out like a regular clinic day. I had a busy morning of clinic patients. As I sat across my 9:00 A.M. patient in the exam room, we conversed with our usual discussion about his family and he was asking about mine. I asked my usual history and review of ophthalmic pertinent symptoms. He noted everything was great and his vision was very stable. As I scooted towards him with my chair to the slit lamp microscope, I noticed he still had his glasses on. I kindly requested that he remove his glasses for the exam. He took them off, looked around a bit while waving them around, and finally placed them very inconveniently in front of my slit lamp joystick. If I had started to use the microscope, it would have crushed his glasses. Simultaneously, he also realized that it was not an appropriate place for the glasses and then decided to quickly take them and try to put them on the side table. Unfortunately, in his haste, the glasses missed the table and fell to the floor. We both looked at each other and he says “Well, where should I put my glasses safely?”. That’s when it hit me: there should be a place that patients can place their eyeglasses safely and securely during the slit lamp microscope examination. That’s when the spark of inspiration occurred! I still had a busy clinic of patients, so I continued working but could not shake off that inspiration euphoria. As I continued seeing more patients, I noted very similar scenarios like the earlier patient interaction with slight variations but overall a single underlying theme: patients have no place to place their eyeglasses during the examination. I observed them putting the glasses on the side of the slit lamp, in front of it, inconveniently giving the glasses to a family member, drop the glasses, and even smash them in their pocket! If you are involved in eyecare and are reading this, you know all the scenarios (and maybe more!) that I am mentioning and have certainly encountered this underlying problem on a daily basis in your practice.

As I returned home, that inspiration evolved into a true idea: designing an eyeglass holder that can attach to the table of the slit lamp microscope (or frankly any table). I sat at my desk and sketched out the first prototype. From this, I went to my local hardware store to gather the raw materials and dusted off my tool set to produce the first prototype of the Mali Eyeglass

Holder. After ensuring its utility and function in clinic, I then proceeded to patent the idea. The next step in the journey (and probably the most daunting originally) was developing the manu-facturing process. There were a few principles that I wanted to uphold during this process: it had to be manufactured here in the USA and I wanted to make sure it would be affordable for the mass public. After considerable efforts, I located a manufacturing facility just 10 miles from my home and perfected the manufacturing process to uphold the highest quality standards. While my family, friends, and patients thought it was a great idea, I wanted to see if I could achieve further validation from the eyecare community at large prior to releasing the product

for mass dis-tribution and retail sales. That’s when I saw an advertisement for The Winning Pitch competition at the ASRS 2018 Annual Meeting (think of Shark Tank for eyecare ideas). At this competition, I ended up winning Honorable Mention which provided me the additional motivation that this prod-uct has significant innovation and considerable excitement to be successful. Now that I had a viable product, the final portion of my journey was setting up a company official-ly, Mali Enterprises. From this, I developed my e-commerce website and now sell the product online direct to consumers. In addition, I am exploring potential licensing opportunities and interna-tional distribution strategies. What started out as inspiration in clinic one day has now become a true industry with retail sales and a patented product. Of course, in the spirit of a true entrepreneur, I must take the opportunity full-on and advertise my product in this article. Please visit my website: www.malienterprises.org to buy your Mali Eye-glass Holder today!

In addition, here are some photographs of the product in action and design specifications: Throughout the whole journey, my greatest inspiration, motivation, and support has been my lovely wife Yasmin, my amazing children Julia and Grant. Yasmin helped me with essentially every step of the process of designing and developing our product and company. With their love and support, I obtain my greatest strength with truly feeling invincible and incredibly confident that I can achieve anything. The other pillar of strength in my life is my religion, The Bah ’  Faith. It gives me a sense of purpose, a beacon of light to follow, and a strong foundation in my life. As an entrepreneur, one will face all types of challenges and it is how you respond to these and overcome them that will determine success. One quotation that really helped me was: ““Men who suffer not, attain no per-fection. The plant most pruned by the gardeners is that one which, when the summer comes, will have the most beautiful blossoms and the most abundant fruit.”1 This has truly been an amazing and educational journey: taking an idea, making an invention, ob-taining a patent, developing a manufacturing process, executing a marketing strategy, and building a company and brand that I am truly proud of is the American Dream. My advice to anyone reading this is if you have a product idea, no matter how simple or elaborate, just go for it. You never know where it will lead you,sky’s the limit. Make sure to keep a laser-like focus and stay true to your values, thus allowing you to achieve your goals and be a successful entrepreneur.



We are pleased to announce the retina and optometric practices awarded the distinction of

AMD Centers of Excellence!


Allisonville Eye Care (Fishers, IN)

Brown Retina Institute (San Antonio, TX)

Carolina Eye Associates, P.A. (North & South Carolina)

Central Massachusetts Retina & Uveitis Center (Ayer, MA)

Central Optometry (London, Ontario)

Charles Retina Institute (Germantown, TN)

Contact Lens & Vision (Woodbridge, NJ)

Dr. Dorothy L. Hitchmoth, PLLC (New London, NH)

Eye Associates of Boca Raton, P.A. (Boca Raton, FL)

Eye Care Plus, LLP (Amarillo, TX)

Eye Health Consultants (The Woodlands, TX)

Eye Luv Lucy Optometry (San Jose, CA)

Eyes on Sheppard (North York, Ontario)

Grin Eye Care (Leawood, KS)

Integrative Vision (Shrewbury, NJ)

Island Retina (Shirley, NY)

Joseph R. Podhorzer, MD, PLLC (Brooklyn, NY)

Kehoe Eye Care, PC (Galesburg, IL)

Krug Optometry (Hays, KS)

Laguna Eyes Optometry (Laguna Beach, CA)

Lipski Eye Center, PC (Lewisburg, PA)

Low Vision Doctors of Ohio (Columbus, OH)

Low Vision Optometry of Southern California (Mission

Viejo, CA)

Low Vision Specialists of Maryland & Virginia (Timonium, MD)

Marshall EyeCare Physicians, PC (Holmdel, NJ)

Medina Vision Centre, Inc. (Medina, OH)

Memorial Vision, PA (Houston, TX)

Mid Florida Eye Center (Mt. Dora, FL)

Mississippi Retina Associates (Jackson, MS)

Ophthalmic Physicians Inc. (Mentor, OH)

Ophthalmology Associates PSC (Louisville, KY)

Orange County Retina (Santa Ana, CA)

Pacific Eye Surgery Center (Honolulu, HI)

Palmetto Retina Center, LLC (West Columbia, SC)

Paul Vision Institute (Wilmington, NC)

Precision Vision Edmond (Edmond, OK)

Premier Eye Care of Eastern Idaho (Idaho Falls, ID)

Professional Eye Care Center (Niles, IL)

Rancho Mirage Eye Care + Optometry (Rancho Mirage, CA)

Retina & Vitreous Consultants of Virginia, P.C. (Winchester, VA)

Retina Associates of Orange County (Laguna Hills, CA)

Retina Associates of Utah, P.C. (Salt Lake City, UT)

Retina Associates of Western NY, P.C. (Rochester, NY)

Retina Consultants of Southern Colorado, P.C. (Colorado Springs, CO)

Retina Macula Specialists of Miami (N. Miami Beach, FL)

Retina Specialists of Ohio (Mayfield Village, OH)

Retinal Consultants of San Antonio (San Antonio, TX)

Rouse Family Eye Care (Sunrise, FL)

Sight Improvement Center, Inc. (New York, NY)

Southern Montana Optometric Center (Laurel, MT)

Stanley J. Hallock, OD (Orlando, FL)

The Eye Associates (Bradenton, FL)

The Macula Center (Clearwater, FL)

The Retina Center (St. Louis, MO)

The VitreoRetinal Eye Center (Biloxi, MS)

Thomas Eye Group (Atlanta, GA)

Toronto Integrated Eye Care (Etobicoke, Ontario)

True Vision Eyecare (Acworth, GA)

Upper Richmond Optometry (Arva, ON)

Valley Eye Clinic (Luray, VA)

Vision Center of Lake Norman (Mooresville, NC)

Vision Health (Turnwater, WA)

Wiles Eye Center (Kansas City, MO)

Woolf Eye Care Center (Gilbert, AZ)




By: Jeffry D. Gerson,

O.D., F.A.A.O.


You may be familiar with AREDS supplements or even the AREDS/ AREDS2 studies and what they mean for patients with macular degeneration. However, these studies set out to do more than just determine which vitamin is best for people with AMD. Due to age, the AMD population is also a group that often is confronted with choices to make regarding cataract surgery. A recent publication discussed the results (from the AREDS2 10-year study) of people with AMD having cataract surgery. Historically, people have been concerned about cataract surgery in people with AMD and that the surgery may cause progression of the AMD. This fear could then prevent cataract surgery that may have been able to improve vision. This study set out to compare results of those who did vs those who did not have cataract surgery in relation to progression to wet AMD or geographic atrophy. At the end of the day, there was no significant difference in likelihood of progression to wet AMD in those that underwent cataract surgery versus those that did not.

This is important for us to know so that a needed cataract surgery is not put off due to an unnecessary fear. Of course, careful monitoring of AMD is important regardless of cataract or surgery status.


Cataract Surgery and the Risk of Developing Late

Age-Related Macular Degeneration: The Age-Related Eye

Disease Study 2 Report Number 27

Ophthalmology 2021 Nov 15;[EPub Ahead of Print], S

Bhandari, S Vitale, E Agr n, TE Clemons, EY Chew

Jeffry D. Gerson, O.D., F.A.A.O.


Eye Food Recipes


Courtesy of The Complete Eye Health & Nutrition Guide

by Laurie Capogna   2019 www.robertrose.ca Reprinted

with permission. Available where books are sold.




Eggs aren’t only for breakfast! This meatless main is a healthy way to enjoy quiche, as it eliminates the need for a pastry shell. It can be prepared ahead of time and enjoyed cold for lunch or dinner, with a mixed green salad. Eye Nutrients: Lutein, zeaxanthin, vitamin C, vitamin E, zinc


Preheat oven to 375∞F (190∞C)

8-inch (20 cm) square baking dish, greased

1 tbsp olive oil 15 mL

2 green onions, chopped 2

1 red or orange bell pepper, chopped 1

3 cups chopped trimmed kale (bite-size pieces)750 mL

1⁄2 cup shredded Cheddar cheese 125 mL

6 large omega-3 eggs 6

1⁄2 cup milk 125 mL

Salt and freshly ground black pepper

1 tbsp chopped fresh parsley 15 mL

(or 1 tsp/5 mL dried)

1 tbsp chopped fresh tarragon 15 mL

(or 1 tsp/5 mL dried)

  1. In a large skillet, heat oil over medium-high heat. Add green onions, red pepper and kale; cook, stirring, for 3 to 5 minutes or until pepper has softened. Transfer to prepared baking dish and sprinkle with cheese. 2. In a large bowl, whisk together eggs and milk. Season with salt and pepper, then stir in parsley and tarragon. Pour over vegetable mixture and stir gently to evenly distribute ingredients. 3. Bake in preheated oven for 18 to 25 minutes or until quiche is set.

Tip: To make this quiche ahead, prepare it through step 3, let cool completely, then cover with plastic wrap and store in the refrigerator for up to 3 days. Variations: In place of the green onions, peppers and kale, try using 2 cups (500 mL) broccoli, 1⁄2 cup (125 mL) sun-dried tomatoes and 1⁄2 cup (125 mL) sliced kalamata olives. Use feta cheese in place of Cheddar.




This dip is a staple at my house when I entertain. It is quick to make and high in fiber and zinc. I always make a double batch and keep some in the fridge to enjoy with veggies or as a sandwich spread later in the week.

Eye Nutrients: Vitamin E, zinc, fiber

Food processor

8 drained oil-packed sun-dried tomatoes,

coarsely chopped 8

1 clove garlic, coarsely chopped 1

2 cups rinsed drained canned cannellini

(white kidney) beans 500 mL

2 tbsp freshly squeezed lemon juice 30 mL

2 tbsp extra virgin olive oil 30 mL

Salt and freshly ground black pepper

  1. In food processor, combine sun-dried tomatoes, garlic, beans, lemon juice and oil; process until smooth. 2. Transfer to a bowl and season to taste with salt and pepper. Serve immediately

or cover and refrigerate for up to 3 day



By Medical Dialogues Editorial Team

Researchers have developed a potential new treatment

for the eye disease glaucoma that could replace daily

eye drops and surgery with a twice- a-year injection to

control the buildup of pressure in the eye.

CREDIT: Rob Felt, Georgia Tech a


Age-related macular degeneration (AMD) is a prevalent eye condition among the elderly. It is

caused by inflammation of the macula, which is the region of the eye that regulates crisp, straight-ahead vision.AMD is now the most frequent cause of visual loss in persons over the age of 50 all over the world. A new study conducted by Meenakshi Ambati and team showed that patients with depression who were treated with fluoxetine had a lower risk of acquiring dry AMD. These data, taken together, point to fluoxetine as a possible drug-repurposing candidate for dry AMD. The findings of this study were published in Proceedings of the National Academy of Sciences of the United States of America. Dry AMD causes vision loss due to deterioration of the retinal pigmented epithelium (RPE). The accumulation of Alu RNAs, which are noncoding

transcripts of a human retrotransposon, contributes to RPE cell death. By activating the NLRP3-ASC inflammasome, Alu RNA causes RPE degeneration. Researchers investigated the possibility of repurposing medications previously licensed for other illnesses to treat dry AMD. An investigational medication known as CY-09 has been discovered to inhibit the inflammatory process that causes dry AMD by attaching to a protein known as NLRP3. The testing procedure necessary to approve a new medicine, on the other hand, might take years or decades. The researchers sought medications that are structurally and functionally comparable to CY-09

that are currently approved by the US Food and Drug Administration (FDA). For more than three decades, fluoxetine has been routinely used to treat depression. The researchers examined health claims data from more than 100 million Americans gathered between 2006 and 2018 to investigate if the medicine may reduce the incidence of dry AMD in persons.

Observations made in this study:

  1. The researchers discovered that fluoxetine—an antidepressant best known by its trademark name, Prozac—was structurally identical to CY-09. Further research in the lab discovered that fluoxetine, like CY-09, may bind to NLRP3.
  2. In cell tests, fluoxetine inhibited the inflammatory cascade initiated by NLRP3 that finally leads to eye injury. Fluoxetine injections into the eye protected the macula against inflammation and degeneration in a mouse model of dry AMD. Eight other antidepressants, on the other hand, did not slow the course of AMD.
  3. After controlling for other characteristics known to be linked with dry AMD, such as age, gender, smoking, BMI, and general health, the researchers discovered that those who used fluoxetine at some point in their life had a 15% decreased chance of getting dry AMD. In conclusion, these discoveries are an intriguing illustration of the potential of drug repurposing, which involves reusing current medications in novel and unexpected ways. Finally, the best method to see if fluoxetine helps macular degeneration is to conduct a prospective clinical study.


Ambati, M., Apicella, I., Wang, S., Narendran, S.,

Leung, H., Pereira, F., Nagasaka, Y., Huang, P.,

Varshney, A., Baker, K. L., Marion, K. M., Shadmehr,

M., Stains, C. I., Werner, B. C., Sadda, S. R., Taylor, E.

W., Sutton, S. S., Magagnoli, J., & Gelfand, B. D. (2021).

Identification of fluoxetine as a direct NLRP3 inhibitor

to treat atrophic macular degeneration. In Proceedings

of the National Academy of Sciences (Vol. 118, Issue 41,

  1. e2102975118). Proceedings of the National Academy

of Sciences. https://doi.org/10.1073/pnas.2102975118




Without ongoing contributions from generous donors like you, the Macular Degeneration Association would be

unable to fund Research and Education for the millions of people living with macular degeneration.




Phone, Mail or Online

Phone: Please call (941)893-4387 today to speak to one of our Donor Services Representatives.

Mail: Send your check or money order today payable to:


5969 Cattleridge Boulevard, Suite 100 | Sarasota, FL 34232

Online: Please visit www.macularhope.org today and click on the Donation tab.

Stocks, Securities, Mutual Funds and IRAs

Please give serious consideration to the donation of stock and mutual fund shares as this offers numerous opportunities

to make a most gracious gift and receive tax advantages.

Wills, Bequests and Planned Gifts

Please give serious consideration to the designation of MDA in your Will, Charitable Trusts, Life Insurance, Appreciated

Securities and Real Estate as this offers preplanned giving opportunities that will serve the macular community for

years to come. Please call Lynne Henry (941)893-4389 at the Macular Degeneration Association, today, for personal

assistance in initiating this effort.

The following language has been reviewed and is deemed a legally acceptable form for including such a bequest in a will:

“I give and bequeath to the Macular Degeneration Association, 5969 Cattleridge Blvd. Suite # 100 Sarasota, FL 34232

for discretionary use in carrying out its aims and purposes, (the sum of $_____) or ( a sum equal to _______% of

the value of my gross estate at the time of my death under this will or any codicil hereto).”

The Macular Degeneration Association Federal ID number is 27-3025707




Honor a family member, friend or special event by donating to MDA. Pay tribute to someone you love whose life

has been impacted by macular degeneration. In lieu of flowers, please consider designating Macular Degeneration

Association as your charity of choice.




Launch a Giving Campaign

Please consider leading a team at work by encouraging your colleagues and staff to join together to help those

living with macular degeneration. Launch a workplace giving campaign today.

Ask about Matching Gifts

Many gracious employers double or even triple charitable donations made by individual employees. Some companies

will match gifts made by retirees and or their spouses. Contact your employer for matching gift eligibility

as this allows you to maximize your personal donation.


Thank you!


Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.